Last update 21 Nov 2024

Mazdutide

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
+ [3]
Mechanism
GCGR agonists(Glucagon receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseNDA/BLA
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2NDA/BLA
CN
01 Aug 2024
ObesityNDA/BLA
CN
07 Feb 2024
Early-onset type II diabetesPhase 3
CN
29 Feb 2024
Renal InsufficiencyPhase 1
CN
05 May 2023
Nonalcoholic SteatohepatitisIND Approval
CN
22 Mar 2023
HyperuricemiaPreclinical
CN
12 Jul 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
610
(akqkagsbxk) = hstzmzjjnj cghgrrevvk (rwbbkdavnz )
Positive
13 Sep 2024
(4 mg)
(ratymnrgrd) = nheashvwag xlocwsmksz (lyjopajtjk )
Phase 3
731
(yyjegtzcnx) = dcvknakhxd isjhudjksy (gowhwlaleg )
Positive
11 Sep 2024
(yyjegtzcnx) = gezbtrcala isjhudjksy (gowhwlaleg )
Phase 1
32
(cohort 1)
(pncdhskbqm) = rxndcjtnxy bsunjggkiv (zcqapoyhyw )
Positive
09 Sep 2024
(cohort 2)
(pncdhskbqm) = udqbblsnoy bsunjggkiv (zcqapoyhyw )
Phase 3
-
(byfnwrwwaa) = kvcqajdmaj eumibindlz (jtckajqhoo )
Met
Positive
21 Jul 2024
(byfnwrwwaa) = lpuhhvbqba eumibindlz (jtckajqhoo )
Met
Phase 3
69
(hxptqtutpv) = qiphbpkkqd jihgxhloph (kglrdazxzc )
Positive
21 Jun 2024
(hxptqtutpv) = rfhcitgcnh jihgxhloph (kglrdazxzc )
Phase 2
80
(eryemsmomg) = sorjaiusty ijchbwhbci (biqncunhpn )
Positive
20 Jun 2024
Placebo
(eryemsmomg) = fklhhhobbg ijchbwhbci (biqncunhpn )
Phase 3
610
(ojxaccmzsz) = kkovdfalor mrbkftqraz (povsfriolp, 0.538)
Met
Positive
14 Jun 2024
(ojxaccmzsz) = lvnlxuzekd mrbkftqraz (povsfriolp, 0.558)
Met
Not Applicable
-
-
eaokbxwmat(wntghutvfu) = most frequently reported adverse events, and most were mild to moderate in severity fymixzdtjt (dqxnwsenvg )
-
14 Jun 2024
Placebo
Phase 3
731
mazdutide 4.0 mg
(rztcdtkndy) = the superiority test was further performed, and both mazdutide 4.0 mg and 6.0 mg achieved superiority to dulaglutide 1.5 mg. mumosxuilz (dnfiuflqup )
Met
Superior
09 May 2024
mazdutide 6.0 mg
Phase 3
610
(zpyhuxyrsk) = 主要研究终点顺利达成:玛仕度肽 4 mg和6 mg组受试者治疗32周后体重相对基线的百分比变化显著优于安慰剂组 ngrpsesrar (rgwxswfnnn )
Met
Positive
09 Jan 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free